TABLE 3.
Drug susceptibility of NJH M. abscessus clinical isolates to a 20-drug panel, reported as MICs
| Drug | MIC (μg/ml) |
No. of resistant isolates/total no. of isolatesa | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NJH1 | NJH4 | NJH5 | NJH6 | NJH7 | NJH8 | NJH9 | NJH10 | NJH11 | ||
| Amikacin | 16 | ≤8 | ≤8 | ≤8 | >64 | 32 | 16 | ≤8 | 32 | 1/9 |
| Kanamycin | 16 | ≤8 | ≤8 | ≤8 | >64 | 32 | 16 | ≤8 | 16 | 1/9 |
| Tobramycin | 16 | 16 | 8 | 8 | >16 | 16 | 8 | 16 | >16 | 6/9 |
| Gentamicin | >16 | 8 | 4 | 8 | >16 | >16 | 16 | 8 | >16 | 5/9 |
| Imipenem | 16 | >16 | >16 | 8 | 8 | 8 | 16 | >16 | >16 | 6/9 |
| Cefoxitin | 64 | 64 | 64 | 32 | 64 | 64 | 32 | 64 | 64 | 9/9 |
| Ceftriaxone | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 9/9 |
| Cefotaxime | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 9/9 |
| Cefepime | 32 | >32 | >32 | >32 | >32 | 32 | >32 | >32 | >32 | 9/9 |
| Clarithromycin | 0.5 | 0.5 | 1 | 2 | 1 | 1 | 1 | >32 | 0.5 | 1/9 |
| Azithromycin | ≤16 | ≤16 | 32 | 32 | 32 | 32 | ≤16 | >256 | ≤16 | 1/9 |
| Amoxicillin/clavulanic acid | >32/16 | >32/16 | >32/16 | >32/16 | >32/16 | >32/16 | >32/16 | >32/16 | >32/16 | 9/9 |
| Ciprofloxacin | 8 | >8 | 8 | 4 | >8 | >8 | 8 | >8 | 8 | 9/9 |
| Moxifloxacin | >4 | >4 | >4 | >4 | >4 | >4 | >4 | >4 | >4 | 9/9 |
| Trimethoprim/sulfa | >4/76 | >4/76 | >4/76 | >4/76 | >4/76 | >4/76 | >4/76 | >4/76 | >4/76 | 9/9 |
| Doxycycline | 16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | 9/9 |
| Minocycline | 8 | >8 | >8 | >8 | >8 | >8 | >8 | >8 | >8 | 9/9 |
| Tigecycline | 1 | 0.5 | ≤0.25 | 2 | 1 | 1 | 0.5 | 2 | 1 | 0/9 |
| Linezolid | >16 | 16 | >16 | 16 | >16 | >16 | 16 | >16 | >16 | 9/9 |
a
Determination of isolates with resistant phenotypes was based on previously defined MIC thresholds specific to each drug.